Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Campath plus high-dose methylprednisolone in p53-deleted CLL
ISRCTN38006233Phase 2Completed
- Sponsor
- University of Liverpool
- Start
- Jun 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab and methylprednisolone in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by University of Liverpool. Primary endpoints: Overall response rate and Minimal residual disease negativity rate. Started Jun 2006; status: completed.
02
Drugs
alemtuzumabmethylprednisolone
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ISRCTN38006233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN38006233.